EU review extended for BioMarin’s gene therapy Valrox
The EMA has asked for full data from an ongoing Phase III study of the treatment in patients with severe haemophilia A
Read More
Tag: valoctocogene roxaparvove
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
